GH provocative tests are required in patients with pituitary tumors, except for those with multiple pituitary hormone deficiencies (≥3 pituitary hormone deficiencies) and low serum IGF-1 levels (< -2.0 standard deviation [SD] score) [2]. This evidence concerns the gene GH1 and pituitary tumor.